Brazil plans Viracept compulsory license
The Brazilian government is continuing its plans to issue a compulsorylicense to commence local manufacture of a generic version of Roche's HIV/AIDS drug Viracept (nelfinavir), if the manufacturer's new price offer on the drug, which is expected next month, is not acceptable.
Viracept pricing negotiations failed in May, after the Brazilian authorities rejected an offer from Roche of a 13% price cut for the drug (Marketletter May 28). However, following the USA's withdrawal on June 25 of a complaint to the World Trade Organization over Brazil's patent law, Roche is expected to come under pressure to offer an acceptable reduction in the drug's price. If this is not the case, the compulsory license is expected to be issued in October.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze